What changed, and what stayed unknown
Tesamorelin Trials: 1 Approved Use, Clear Limits
Most trials involved people with HIV. They checked two kinds of internal fat, sugar in blood, and harm across weeks or months.
What did tesamorelin trials show most clearly?
Most trials enrolled people living with HIV. Their bodies stored too much fat near organs. The work didn't cover routine weight loss.
Organ fat fell about 15-18%. Liver fat also dropped. The soft layer under your skin barely changed.
Your body weight barely changed too. IGF-1, a liver-made hormone, rose. That rise needs a long safety view.
This hormone helps cells grow and divide. Extra growth messages might also help hidden cancer grow. Trials haven't settled that risk over many years.
The organ fat came back once treatment ended. You'll see who was tested and for how long. Each small source number opens the matching paper.
How much organ fat changed in trials?
Both trials enrolled HIV patients. They weren't weight-loss trials. The first was a 26-week study with 412 people. You may not match them.
This Phase 3 trial was large and late. People got 2 milligrams each day. Organ fat fell with tesamorelin. It rose with placebo.
Triglycerides, one blood fat, fell 50 milligrams in each deciliter of blood. Placebo raised them 9 milligrams per deciliter. Doctors call one-tenth of a liter a deciliter. The paper gives no starting or healthy range for you. Researchers treated the fall as better [1]. They also measured IGF-1.
The 52-week study had 273 people taking tesamorelin. Another 137 received placebo. Organ fat stayed 18% lower [2]. Your blood sugar may not match theirs.
A separate 6-month trial followed 50 adults taking HIV drugs. One slice of their belly scans showed 42 square centimeters less organ fat [3]. That area isn't your total body weight.
Reviewers combined five controlled trials in 2026. They found less organ and trunk fat. People kept a little more muscle.
Their math gave 95% confidence that organ fat truly fell. No serious harm was reported [15]. The result still applies only to those patients, not directly to you.
Another review used the same Phase 3 trials. It measured one slice of each belly scan. Below 140 square centimeters counted as a strong response, not your target. More people on tesamorelin crossed that mark. The authors had 95% confidence that chance didn't explain it [14].
What changed in the liver and blood?
The liver result came from HIV patients. It wasn't an approved liver treatment. You can't treat it as one.
One trial found less liver fat [3]. A 2026 paper summed up five trials. The result was the same [15]. Less fat didn't prove less liver damage for you.
Another trial checked two blood proteins tied to inflammation, your body's alarm response. A clotting-related protein fell. A protein from fat cells rose as organ fat fell [12]. Researchers viewed both changes as better. People didn't report feeling them.
An X-ray scan study measured fat tissue, not just its amount. A denser reading can mean fat cells hold less fat. Both deep and soft fat became denser [13]. The study didn't prove better health for you or extra fat loss.
Which tesamorelin safety checks mattered?
Trials watched changes caused by more growth hormone. They checked blood sugar and IGF-1 [1][2]. That liver-made hormone was 1 key safety check.
A federal report found no liver injury clearly caused by tesamorelin [5]. The short trials can't settle harm after many years.
The blood-sugar study was small. It included only 13 healthy men. It lasted two weeks. That isn't a final answer for you.
Fasting sugar didn't change. Their bodies also handled sugar normally after insulin [4].
Across the 52-week HIV work, sugar changes didn't alter care [2]. Smaller shifts can still happen. Your doctor can check blood during approved care. Trials don't settle your own risk.
How safe did tesamorelin look during trials?
The studies were short and mostly involved HIV patients. They can't settle safety across many years. They also don't cover everyone like you.
Within those limits, no major warning appeared. A 2026 review covered five trials. Reviewers found no serious harm [15].
A federal report found no liver injury clearly caused by the drug [5]. Insulin still worked normally in healthy men [4].
The benefit didn't last after treatment ended. Organ fat returned in the 52-week work [2]. Continued treatment had been needed.
The time limit matters for you. Weeks to a year isn't lifetime proof. No large routine weight-loss trial has filled that gap.
Why does tesamorelin raise 1 cancer question?
The cancer question isn't settled. Tesamorelin raises IGF-1, which helps cells grow. In theory, extra growth messages could also help an unseen cancer grow.
Across 52 weeks, cancer didn't rise in the main trials [2]. Keep 3 limits in mind. That span wasn't a lifetime. The trials were too small to find rare harm.
Active cancer rules out the approved drug [5]. Cancer risk across many years is unknown. A quiet short trial can't erase your risk.
That gap weakens support for broad use. FDA hasn't approved anti-aging, sports, or routine weight-loss use [5].
Who can't use approved tesamorelin?
You can't receive the approved drug with active cancer [5]. Tesamorelin raises IGF-1. This hormone supports cell growth. Cancer safety over many years isn't settled.
Pregnancy is another listed reason. Athletes can't use the drug during or outside competition.
Research-grade material belongs only in a lab. It isn't made for you to inject. It lacks the checks applied to approved medicine.
Who had a larger organ-fat change?
People didn't all respond alike. Reviewers combined two large trials. They included 543 people on tesamorelin and 263 on placebo.
They measured one slice of each belly scan. Less than 140 square centimeters of organ fat counted as a strong response. That's a study line, not your goal. More people on tesamorelin crossed it. The authors had 95% confidence that chance wasn't the reason.
The review found 3 clues tied to a bigger change. Some began with too much sugar and fat in their blood. White patients responded more often too [14]. The study didn't explain why. Race alone can't predict your result.
At three months, researchers couldn't yet spot responders. They needed more time. An early change can't promise what comes next.
An X-ray scan study ran 26 weeks. Denser readings can mean fat cells hold less fat. Both deep and soft fat became denser [13]. The work didn't show extra fat loss or better daily health.
These were still HIV patients. Back at the top of this page, the main limit remains. No study can predict your own scan.
What do all tesamorelin trials tell you?
Results leaned the same way within narrow limits. Most people tested had HIV. There isn't a large routine weight-loss trial for you.
Organ fat fell by 26 weeks. The drop held at 18% through 52 weeks. Five trials combined also found less organ fat.
IGF-1 rose 81% in the main trial. In healthy men, the level rose 181 millionths of a gram per liter of blood. Those studies can't prove that rise safe for you over many years.
Liver fat fell too. Other scans suggested fat cells held less fat [1][2][4][3][13][15]. The studies didn't show that people felt better from that scan change.
The limits stayed firm. Organ fat returned after treatment ended. That hormone rise keeps the long cancer question open.
No product review can close that question. A broad weight-loss claim can't either. You have only the tested groups and time spans [2][5].